Structure via PubChem · Public domain (PubChem)
lorlatinib
Sign in to saveAlso known as PF-6463922
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), two enzymes that play a role in the development of cancer. It was developed by Pfizer.
Key facts
- Drug.image
- Lorlatinib Structure.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Lorbrena, Lorviqua
- Drug.MedlinePlus
- a619005
- Drug.DailyMedID
- Lorlatinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- ED05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 81%
- Drug.protein_bound
- 66%
- Drug.metabolism
- Mainly CYP3A4 and UGT1A4
via Wikipedia infobox
Chemical data
- Formula
- C21H19FN6O2
- Molecular weight
- 406.4 g/mol
- IUPAC name
- (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
- SMILES
- C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
- InChIKey
- IIXWYSCJSQVBQM-LLVKDONJSA-N
- XLogP
- 1.5
- Polar surface area
- 110 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2018
- Admin. routes
- oral
- Indications
- non-small cell lung carcinoma, neuroblastoma, neoplasm, anaplastic large cell lymphoma
via ChEMBL · EBI
Research
845 papers- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.The New England journal of medicine · 2020
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
- A pragmatic guide for management of adverse events associated with lorlatinib.Lung cancer (Amsterdam, Netherlands) · 2024
- Lorlatinib.2012
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.The Lancet. Respiratory medicine · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 406.155
- Has use
- medication
Show 6 more facts
- canonical SMILES
- CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
- chemical formula
- C₂₁H₁₉FN₆O₂
- Commons category
- Lorlatinib
- isomeric SMILES
- C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
- subject has role
- protein kinase inhibitors
- medical condition treated
- non-small-cell lung carcinoma
via Wikidata · CC0
~7 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- Research
- References
- External links
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), two enzymes that play a role in the development of cancer. It was developed by Pfizer.
The most common adverse reactions include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough.
Excerpted from Wikipedia’s “lorlatinib” article, available under the CC BY-SA 4.0 licence.